//
Sneak Preview
Xalkori And The Art Of Modern Drug Development / Pfizer developed crizotinib and its companion diagnostic in just four years after identifying an aberrant ALK gene as the target, spanning a corporate restructuring, the Wyeth integration, and the departure of senior staff in the R&D organization and oncology BU. The next year or so will tell whether Xalkori was a flash in the pan, or whether it marks the long awaited turnaround for Pfizer’s oncology business and a model for nimble drug development.
Current Issue:
January 2012
Feature Articles
Biopharma In 2011: A Year Of Transition / If 2010 was the year when pharma introduced new models, 2011 was the year it discovered that executing on its plans required a new mindset. There was a realization that pharma input and capital were required at the earliest stages of company creation. / IN VIVO January 2012
Top Device Stories Of 2011: Living In A State Of Transition / EBI’s device team reviews of the top news stories in the medical device industry in 2011. Top stories include: 510(k) reform, user-fees, VC money dries up for medtech, hot clinical spaces of the year, where private investment dollars went in 2011, big changes at J&J, and the new physician/hospital alignments and their impact on the medical device industry. / IN VIVO January 2012
Trends In Diagnostics 2011 /
In the 1967 movie classic The Graduate, Dustin Hoffman gets a one-word piece of career-planning advice from a family friend: “plastics.” In diagnostics, as it was last year, that word would have to be sequencing. But unlike last year, when the first item in our diagnostics trends piece cited the successful IPOs of next-generation sequencing companies Pacific Biosciences of California Inc. and Complete Genomics Inc., owing to the downturn in government funding and a slow economy, the tone in 2011 was more nuanced. [See Deal][See Deal] (See"Personalized Medicine In 2010: Welcome To The Esta... / IN VIVO January 2012
Reverse Innovation: Is The US Losing Its Edge In Innovation? / Is US-style innovation in the medical device industry heading towards extinction? Gone are the days when companies believed they could build robust businesses by serving largely, if not exclusively, the US market. / IN VIVO January 2012
Genomics Through The Lens Of Precompetitive Data Sharing / With low-cost whole genome sequencing on the horizon, issues around acquiring and assessing large data sets of sequence information are front and center. The value proposition is also shifting, from the means of acquiring data to their interpretation. / IN VIVO January 2012
As TAVI Advances, Adjunctive Devices Multiply / As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need. As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need. / IN VIVO January 2012
Restructuring for Success: Shifting Biotech Strategies / During a panel discussion at Elsevier Business Intelligence’s Therapeutic Area Partnerships conference in Boston in December 2011, experienced investors and biotech executives drew lessons from difficult restructurings and successful transitions. / IN VIVO January 2012
Around The Industry
Biotech’s Declaration Of Independence And What Pharma Needs To Do About It / After a long period when only the bravest, well-funded biotechs attempted to build a commercial organization, more companies than ever are taking the go-it-alone plunge. Campbell Alliance thinks we may look back on the commercializing classes of 2011–2012 for key lessons on what drives success, which companies created value and how, and when market challenges prove too much for a new organization. / IN VIVO January 2012
Bioventus Spin-out Creates New Leader In Orthobiologics / The spin-out of Smith & Nephew’s Biologics and Clinical Therapies division into a privately held entity, Bioventus LLC may serve as a model for other large publicly held device companies seeking to maximize the performance of non-core businesses. / IN VIVO January 2012
Biopharma Out-licensing: 2012’s “In” Thing? / Talk to any big pharma business development executive about dealmaking trends for more than 15 minutes and the word out-licensing is bound to crop up. But are major drugmakers moving beyond the rhetoric and actually giving up rights to individual assets that heretofore would have been deemed too valuable to merit out-licensing? / IN VIVO January 2012
Deals In Depth
2011’s Top Biopharma Dealmakers / Big Pharma entered into fewer in-licensing deals in 2011 than it did in 2010. Top M&As focused on emerging markets. / IN VIVO January 2012
Deals In Depth: November 2011 / Otsuka and Lundbeck signed a long-term CNS collaboration worth $1.4 billion. Gilead spent $10.4 billion on HCV company Pharmasset, the largest amount ever paid for a clinical-stage biotech. / IN VIVO January 2012
Emerging Company Profiles
Out Of The Blocks / Brief profiles of these recently formed companies: Blend Therapeutics, cetics healthcare technologies, Clearside Biomedical, Perosphere, Rivanna Medical and Trifectas Medical. / IN VIVO January 2012
Start Up Previews
Start-Up Previews / This Month's Profile Group: Artificial Retinal Devices Help The Blind To See, features profiles of 2C Tech Corp., LambdaVision and Nano Retina. Plus these Start-Ups Across Health Care: Adenovir Pharma, Akrivis Technologies, Emboline and Phagenesis. / IN VIVO January 2012
On The Move: A Personnel Database
On The Move / Recent executive-level company changes and promotions in the biotech, pharmaceutical and medical device industries. / IN VIVO January 2012
Deals Shaping The Medical Industry
Deals Shaping The Medical Industry (01/2012) / The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. / IN VIVO January 2012
Publishers Spotlight
19th Annual Euro-Biotech Partnering Summit / Publisher’s Spotlight: Join us in Paris, France from May 30-June 1, 2012 for the 19th Annual Euro-Biotech Partnering Summit. This year’s theme is Changing the Business Model: Drawing on Global Examples of Innovation to Find New Products and Maximize Efficiency. / IN VIVO January 2012
9th Annual Pharmaceutical Strategic Outlook (PSO) Conference, April 11-13, 2012 /
Join us at PSO 2012 where we will delve into the top issues affecting the pharma industry. Experience a dynamic three days of networking and discussion - with a personal and interactive setting, in-depth on-stage interviews, thought-provoking panels, one-on-one partnering meetings and innovative company presentations by carefully selected biotech companies. / IN VIVO January 2012
IN3 Medical Device 360° 2012 – Orlando / Publisher’s Spotlight: Register today for The Investment in Innovation (IN³) Medical Device 360° Conference, being held February 29-March 2, 2012, at the Ritz-Carlton Orlando, Grande Lakes and take your company to the next level. / IN VIVO January 2012